About us
There is no pharmacological intervention in the market that enhances the implantation process through a direct effect on the endometrium. Oxolife’s innovation is a first-in-class oral drug for the treatment of infertile women, named OXO-001, that increases embryo implantation success and pregnancy rates.
Currently, there is no specific drug commercially available for Polycystic ovary syndrome (PCOS),the most common endocrine disorder that affects 10-15% of childbearing age women. So far, the drugs that have been used to treat this syndrome have been directed at the symptoms but not at the syndrome itself.
At Oxolife, we are also studying the use of our drug OXO-001 to treat infertility associated with PCOS, where the pregnancy success rate is still very low despite the existing treatments
Mission
Bring to market the first treatment that improves embryo implantation.
Vision
Improve women’s fertility worldwide, simplifying the process that women and couples with infertility go through. At the same time, we are committed to provide the first implantation treatment available to the scientific community and to improve the understanding of implantation processes.
Values
We are guided by values of excellence, rigor, perseverance, determination, honesty, and team empowerment.
Mission
Bring to market the first treatment that improves embryo implantation.
Vision
Improve global women's fertility and scientific understanding of implantation processes.
Values
We are guided by values of excellence, rigor, perseverance, determination, honesty, and team empowerment.